Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Efsitora Alfa vs Insulin Degludec in Type 2 Diabetes (QWINT-3)
NCT05275400Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2022
- Primary completion
- May 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of Insulin efsitora alfa in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Hemoglobin A1c at 26 weeks. Started Mar 2022; status: completed.
02
Drugs
Insulin efsitora alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05275400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275400.